TetraKit Technologies is a cutting-edge brand dedicated to transforming the development and preparation of theranostic radiopharmaceuticals. With their revolutionary radiolabeling platform, TetraKit, they offer a universal solution for radiolabeling any targeting vector. This breakthrough technology not only makes treatments more powerful but also enhances accessibility and cost-effectiveness for patients with metastatic cancer.

Combining state-of-the-art expertise in synthetic chemistry, radiopharmaceutical chemistry, and nuclear medicine, TetraKit Technologies is leading the way in developing the next generation of theranostics. Their key innovations stem from the pioneering work of co-founder and CSO Matthias Herth's laboratory at the University of Copenhagen. As a spin-off from the university, TetraKit Technologies is well-positioned to channel the latest advancements in click chemistry into their products.

In addition to the core radiolabeling platform, TetraKit Technologies also focuses on creating novel and proprietary theranostic radiopharmaceuticals based on the TetraKit platform. Founded in 2021, TetraKit Technologies is driven by a talented team of experts who are dedicated to pushing the boundaries of radiopharmaceutical development. For inquiries or more information, you can contact TetraKit Technologies at their headquarters in Copenhagen, Denmark